Prasinezumab is a monoclonal antibody that selectively binds aggregated α-synuclein. Prasinezumab is under investigation as a disease-modifying therapeutic candidate for early-stage Parkinson’s disease, where it is being evaluated for its ability to interfere with pathogenic α-synuclein aggregation and progression of neurodegeneration.